Skip to main content
Premium Trial:

Request an Annual Quote

CareDx, Weill Cornell Codeveloping Kidney Transplant Rejection Test

NEW YORK – CareDx said on Tuesday that it has formed an exclusive partnership with Weill Cornell Medicine to develop and commercialize UroMap, a urine-based gene expression test for acute cellular rejection in kidney transplant recipients.

The company said it is collaborating with Weill Cornell on a multiyear research collaboration with exclusive rights to bring UroMap to patients. CareDx obtained the exclusive rights to the UroMap technology through a license agreement with Cornell University. Specific financial terms of the deal were not disclosed.

UroMap was developed by Manikkam Suthanthiran, Weill Cornell's chief of nephrology, hypertension, and transplantation medicine, and his collaborators. In a study in the New England Journal of Medicine, the researchers found that UroMap was able to distinguish acute rejection episodes with high accuracy, and may predict future development of an acute rejection episode, CareDx said.

"UroMap provides early detection and quantification of clinically relevant cellular rejection," Suthanthiran, who is also the named inventor on the patent for the urine gene expression technology, said in a statement. "We are hopeful that this test will benefit kidney transplant patients."

CareDx already sells its own kidney transplant rejection test called AlloSure, a noninvasive blood test that measures transplant injury via donor-derived cell-free DNA. The firm upgraded AlloSure last November in order to detect signs of borderline, subclinical T-cell mediated rejection.

"We are delighted to announce this collaboration with Weill Cornell Medicine to help bring UroMap's rapid allograft rejection detection capabilities to our industry-leading suite of transplant care solutions," added CareDx CEO Peter Maag. "We continue our commitment to fund research and drive innovation for transplant patient care."

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.